Advanced Therapies Europe 2020

29TH - 30TH SEPTEMBER 2020


Phacilitate Leaders Europe Agenda


Plenary Discussion: How can the European market remain competitive on a global stage

17 Sep 2019

This discussion will focus on:

  • Why manufacture in Europe?
  • Are we continuing to produce ATMPs in a cost-effective way?
  • Will Brexit bring more complexity in supply chain?
  • Investment opportunities in Europe vs. in the US - are we maintaining a competitive advantage for biotechs in Europe?
Emanuele Ostuni , Head Of Europe, Cell And Gene Therapy - Novartis
Nicholas Medcalf, Deputy Challenge Director, Medicines Manufacturing - Innovate UK
Jason Slingsby , Chief Business Officer - Oxford Biomedica
Markwin Velders, VP Operations & Managing Director - Kite Pharma EU B.V. in Amsterdam
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd